Represented Xiaomi, in an expedited FRAND global rate setting action concerning Panasonic’s portfolio of 3G and 4G SEPs. The case involved numerous ground-breaking firsts including securing an undertaking from the licensor to be bound by the decision of the English Court and the award of an Interim Licence pending the determination of final FRAND terms by the court: [2024] EWCA Civ 1143; [2023] EWHC 2872 (Pat); [2023] EWHC 2871 (Pat); etc.
Represented Lenovo in implementer led FRAND rate setting action seeking the determination of a rate for InterDigital’s entire patent portfolio, involving complex questions of jurisdiction.
Represented Lenovo in the technical patent trials of significant FRAND action between InterDigital and Lenovo before the English High Court, which resulted in court’s second ever FRAND determination.
Representing world’s leading cellular chipset maker MediaTek in SEP/FRAND litigation against Huawei, including in relation to challenge to the jurisdiction of the English court brought by Huawei.
Represented Pfizer, Warner-Lambert and Viatris in follow-on damages inquiry against the Department of Health, NHS bodies and numerous generic companies arising from cross-undertakings in damages given during the pendency of substantive patent proceedings covering the blockbuster medicine Lyrica® (pregabalin) for treating pain.
Represented British American Tobacco in a series of UK proceedings against Philip Morris, and coordinating proceedings in Europe and beyond, on patents concerning potentially reduced-risk products including tobacco heating, vaping/e-cigarettes, and modern oral products.
